Exhaled nitric oxide monitoring does not reduce exacerbation frequency or inhaled
corticosteroid dose in paediatric asthma: a randomised controlled trial
Authors and email addresses
Katharine Pike1, 4, katypike@soton.ac.uk
Anna Selby2, annaselby@doctors.org.uk
Sophie Price2, saprice@doctors.org.uk
John Warner3, j.o.warner@imperial.ac.uk
Gary Connett2,4, gary.connett@uhs.nhs.uk
Julian Legg2,4, julianplegg@uhs.nhs.uk
Jane SA Lucas1,4, jlucas1@soton.ac.uk
Sheila Peters5, sheila.peters@porthosp.nhs.uk
Hannah Buckley5, hannah.buckley@porthosp.nhs.uk
Krzysztof Magier6, christopher.magier@iow.nhs.uk
Keith Foote7, keith.foote@wehct.swest.nhs.uk
Kirsty Drew2, kdrew13@hotmail.com
Ruth Morris2, ruth.morris@uhs.nhs.uk
Nikki Lancaster2, the5lancasters@tiscali.co.uk
Graham Roberts1,4, g.c.roberts@soton.ac.uk
Affiliations
1 University of Southampton Faculty of Medicine, Southampton, United Kingdom
2 Southampton University Hospital NHS Trust, Southampton, United Kingdom
3 Biomedical Research Centre Imperial College and Imperial College Healthcare NHS Trust,
London, United Kingdom
1
4 NIHR Respiratory Biomedical Research Unit, Southampton University Hospital NHS Trust,
Southampton, United Kingdom
5 St Mary’s Hospital, Portsmouth, United Kingdom
6 St Mary’s Hospital, Newport, Isle of Wight, United Kingdom
7 Royal Hampshire County Hospital, Winchester, United Kingdom
Corresponding author:
Professor Graham Roberts
Human Development and Health,
University of Southampton School of Medicine,
Tremona Road
Southampton SO16 6YD
g.c.roberts@soton.ac.uk
Phone: +44(0)23 80 796160 Fax:
+44 (0)2380 878847
AUTHORS CONTRIBUTIONS
The study was conceived by GR and developed with the other authors. KP, NL, KD, RM, AS
and SP assessed the study participants. KP and GR analysed the study data and prepared the
first draft of the manuscript. All the authors reviewed and discussed the data and approved
the final manuscript.
No authors have any conflicts of interests with respect to this paper.
2
ABSTRACT
Introduction
Inhaled corticosteroid therapy (ICS) for asthma is currently modified according to symptoms
and lung function. Fractional exhaled nitric oxide (FENO) has been demonstrated to be a
non-invasive marker of eosinophilic inflammation. Studies of FENO-driven asthma
management show variable success.
Objectives
This study aimed to evaluate whether monitoring FENO can improve outpatient management
of children with moderate to severe asthma using a pragmatic design.
Methods
Children aged 6-17 years with moderate to severe asthma were recruited. Their asthma was
stabilised before randomisation to FENO-driven therapy or to a standard management group
where therapy was driven by conventional markers of asthma control. ICS or long-acting
bronchodilator therapies were altered according to FENO levels in combination with reported
symptoms in the FENO group. Participants were assessed 2-monthly for 12 months. ICS dose
and exacerbation frequency change were compared between groups in an intention to treat
analysis.
Results
Ninety children were randomised. No difference was found between the two groups in either
change in corticosteroid dose or exacerbation frequency. Results were similar in a planned
secondary analysis of atopic asthmatics.
Conclusion
FENO-guided ICS titration does not appear to reduce corticosteroid usage or exacerbation
frequency in paediatric outpatients with moderate to severe asthma. This may reflect
3
limitations in FENO-driven management algorithms, as there are now concerns that FENO
levels relate to atopy as much as they relate to asthma control.
Trial registration: Controlled-Trials ISRCTN50872816.
Keywords: asthma, exhaled airway markers, paediatric, therapy
The trial was approved by Southampton and South West Hampshire Research Ethics
Committee (06/Q1702/9) and registered with Controlled-Trials.Com (ISRCTN50872816).
Informed consent was obtained from each child’s parents.
INTRODUCTION
Asthma is a disease of airway inflammation [1]. Sputum eosinophil count-guided
management has been shown to reduce exacerbation frequency in adult patients without
increasing inhaled corticosteroid dose [2]. However, sputum induction can be difficult in
young children [3]. Inhaled corticosteroid therapy (ICS) in asthmatic children is currently
modified according to symptoms and lung function, both of which poorly reflect airway
inflammation [4] and poorly predict exacerbations [5]. A suitable clinical measure of airway
inflammation might enable optimisation of individual patients’ ICS dose.
Fractional exhaled nitric oxide (FENO) has been proposed as a non-invasive measure of
eosinophilic inflammation which can be measured in children [6] and may be a marker of
asthma control. [7-10] Asthmatic subjects have higher mean FENO concentrations than nonasthmatic controls [11] and FENO has been shown to increase with worsening asthma control
[6] and with allergen exposure in children with grass pollen-induced asthma [9] Inhaled
corticosteroids have been shown to reduce FENO in children with asthma [12]. Together
4
these observations suggest that FENO varies with the severity of airway inflammation and
may therefore provide a useful marker of disease severity.
Proof of concept studies suggest that adjusting ICS dose according to monitored airway
inflammation might improve clinical outcomes in asthma. Individual studies have suggested
FENO monitoring results in fewer exacerbations [2], lower corticosteroid requirements [13],
reduced airway responsiveness [14] and improved lung function [15]. However, a recent
meta-analysis concluded that, although interventions based upon FENO reduce corticosteroid
use in adults, FENO-monitoring drives up corticosteroid doses in children [16]. Exacerbation
frequency was not significantly affected in either children or adults [16].
Previous studies have shown FENO to add little to asthma management [13-15;17-18]; this
might reflect problems with patient selection, dose-adjustment protocol, or the frequency of
FENO monitoring or corticosteroid dose adjustment. Few previous studies focused upon
moderate-severe asthma. Studies of mild-moderate asthma may have been underpowered
with respect to exacerbations. This prospective, randomised, double-blind study was designed
to be pragmatic, reflecting actual clinical management in paediatric outpatients, and aimed to
assess whether FENO-directed therapy can reduce ICS dose or exacerbation frequency.
5
METHODS
Participants
Participants were recruited from outpatient clinics at Southampton University Hospital, St
Mary’s Hospital, Portsmouth, St Mary’s Hospital, Isle of Wight and the Royal Hampshire
County Hospital, Winchester. Inclusion criteria were age 6-17 years, clinical diagnosis of
asthma and treatment with 400 mcg/day beclomethasone/budesonide or 200 mcg/day
fluticasone. Asthma diagnosis was based upon a history of typical symptoms, 15% increase
in forced expiratory volume in 1 second (FEV1) with bronchodilator or diurnal peak
expiratory flow (PEF) variability 15% [19]. Exclusion criteria were inability to perform
spirometry or FENO measurement, cigarette smoking, poor treatment adherence, lifethreatening exacerbation or need for maintenance oral prednisolone.
Protocol
Participants completed a PEF diary, a paediatric asthma quality of life assessment (PADQLQ)
[20], and underwent aeroallergen skin prick testing (house dust mite, grass pollens, tree
pollens, cat and dog; ALK-Abelló, Hørsholm, Denmark). Participants with a clinical history
of IgE-mediated food allergy, rhinitis or eczema, or one or more skin prick tests 3mm
diameter were considered atopic. Participants’ asthma was stabilised if necessary over 4-16
weeks prior to randomisation. Computer-generated random numbers were used to assign
participants at enrolment to either FENO-based or standard management. Participants were
block randomised according to recruitment centre and randomisation was stratified by
inhaled corticosteroid dose (400-800 mcg/day or > 800 mcg/day beclomethasone equivalent).
Group allocation was recorded by a research nurse and communicated to an independent
clinician responsible for therapy decisions. All participants were assessed identically at each
6
subsequent visit so that participants and the medical staff assessing asthma control were
unaware of group allocation. Participants were assessed 2-monthly for 12 months.
At each visit, a single measure of FENO (blinded to the patient, family and assessing
clinician) was taken by a research nurse according to ATS/ERS guidelines, using a portable
monitor (NIOX MINO; Aerocrine, Solna, Sweden) [6, 21]. After FENO measurement, FEV1
was measured according to ATS/ERS guidelines [22] using a portable spirometer (KoKo
version 4; PDS Instrumentation; Louisville, USA). Finally, an assessing clinician (blinded to
allocation group and FENO) assessed treatment adherence by direct questioning, recorded
exacerbations and administered a questionnaire reviewing symptoms and reliever use over
the preceding two months [modified from 23].
Exacerbations were defined as 48 hours of increased asthma symptoms or therapy, or
decreased PEF (≥ 25%) and classified as mild (requiring increased bronchodilator therapy
only); moderate (requiring systemic corticosteroids); or severe (requiring ≥ 8 hours admission)
[modified from 13, 24]. The blinded clinician categorised participants’ asthma as well
controlled (symptoms and reliever inhaler < 1 per week and FEV1 90% predicted);
controlled (symptoms or reliever inhaler use 1-2 days per week, or FEV1 80% predicted),
or poorly controlled (symptoms or reliever inhaler use > 2 days per week, or FEV1 < 80%
predicted) [modified from 13].
Therapy decisions were taken by a clinician independent of participant assessment following
a simple algorithm reflecting symptom control for standard management subjects, and FENO
measurements in addition to symptom control for the FENO group (Table 1). Under standard
management, therapy was increased if symptoms were poorly controlled and decreased if
7
symptoms were well controlled for 3 months as per the SIGN/BTS guidelines [25](Table 2).
In the FENO group levels of FENO guided therapy. ICS was decreased if FENO 15ppb and
symptoms were controlled or well controlled for 3 months in similar steps as for the standard
management group. Where asthma was poorly controlled and FENO was < 25ppb in the
FENO group, long-acting beta-agonist (LABA) therapy was maximised before ICS were
increase. ICS was increased if FENO 25ppb or FENO doubled from baseline. If FENO
remained raised after increasing by two SIGN/BTS steps, ICS was not further increased
unless participants were poorly controlled.
Statistical analysis
Change in ICS dose and exacerbation frequency over 12-month’s follow-up was compared
between FENO and standard management according to intention to treat. Corticosteroid
doses were calculated as beclomethasone equivalents (mcg). For subjects with incomplete
follow-up, the number of exacerbations was divided by the number of months’ participation
then multiplied by 12 to provide 12 month’s data. Two sample t-tests were used for normally
distributed data, otherwise two sample Mann-Whitney rank-sum tests were undertaken. A 5%
significance level was used throughout. Planned secondary analyses were performed: (1) per
protocol analysis restricted to subjects with complete follow-up and (2) analysis considering
restricted to participants with atopic asthma. Stata® 11 (Stata Corp., College Station, TX) was
used for all analyses.
We calculated that data from 90 subjects would provide power to detect the difference
between a 200 and 100 mcg reduction (SD 150 mcg) in inhaled corticosteroid dose in the two
groups assuming 80% power and < 5% significance level. There would also be 80% power to
detect a 20% reduction in exacerbation frequency in the FENO group assuming 2
8
exacerbations per year (SD 0.75) in the standard management group.
9
RESULTS
Of the 96 children screened, 90 met the inclusion criteria (Figure 1) and were randomised; 44
to FENO-based (49%) and 46 to standard management (51%). The two groups were well
matched at baseline for demographic and clinical features (Table 3). Thirteen (14%)
participants had incomplete follow-up; ten from the FENO group and three under standard
management. Eleven participants withdrew at their request, one was withdrawn due to nonadherence, and one following a life-threatening exacerbation (Figure 1). The groups remained
well matched when subjects with incomplete follow-up were excluded (data not shown).
In total 584 visits were conducted, symptoms were assessed as controlled on 348 occasions
(59.6%), well controlled on 115 (19.7%) and poorly controlled on 121 (20.7%). Therapy was
unchanged on 365 visits (62.5%), increased on 129 (22.1%) and decreased on 90 (15.4%).
When therapy was increased in the FENO group this reflected FENO alone on 44 occasions
(50.0%), symptoms alone on 13 occasions (14.8%) and on 31 occasions (35.2%) both
elevated FENO and poor control was recorded. Of the 43 therapy reductions observed in the
standard management group 25 occurred with FENO > 15 ppb and would not have occurred
had the participant been allocated to the FENO group.
Inhaled corticosteroid dose
As ICS data were highly skewed, median values are reported and non-parametric tests
applied. ICS dose did not change significantly between initial and final visit in either group
(FENO p=0.901, Standard p=0.498) (Table 4). There was no significant difference between
groups in ICS dose at either the initial (visit 0) or final visit (visit 6), nor in change of ICS
dose during the trial (Figure 2 and Table 4). Thirty-four children in the FENO group and 43
under standard management completed 12 months’ follow-up. When analysis was restricted
10
to participants with complete follow-up, the ICS dose change was not significantly different
between groups (p=0.670) and there was no significant between group difference in total ICS
dose received during follow-up (data not shown). Similarly, no between group difference in
ICS dose change was seen after restricting the analysis to the 68 children who were atopic
(p=0.129) (data not shown).
Exacerbation frequency
Thirty seven subjects in the FENO group (84.1%) and 38 in the standard group (82.6%)
experienced at least one exacerbation during follow-up. Of these, five in the FENO (11.4%)
and three in the standard group (6.5%) experienced a severe exacerbation. The number of
subjects experiencing an exacerbation did not differ between groups (p=0.850) (Table 4);
neither was there a difference between the groups regarding the number of subjects
experiencing a severe exacerbation (p=0.420). Time to first exacerbation did not differ
between groups (p=0.391) (Figure 3). There were no significant between group differences
for either overall exacerbation frequency or for frequency of mild, moderate or severe
exacerbations.
There was no between group difference in exacerbation frequency when in order to avoid the
possible complication of seasonality of exacerbations the analysis was restricted to children
with complete follow-up (data not shown). Moreover there was no between group difference
when the analysis was restricted to atopic children (data not shown).
FENO and lung function
FENO measurements were compared between groups. Neither group experienced a
significant change in FENO during follow-up (mean (95% CI) +3.1 ppb (−5.5 - +11.6 ppb)
11
FENO and +3.3 ppb (−8.5 - +15.1 ppb) standard group). There were no significant between
group difference in FENO at any study visit (including baseline) (Figure 4), or in change in
FENO during follow-up. Neither FEV1, FVC nor FEF25-75% change during follow-up differed
significantly between groups (data not shown).
12
DISCUSSION
Neither inhaled corticosteroid therapy nor exacerbation frequency differed significantly
between children with moderate-severe asthma randomised to either standard or FENO-based
management. The two groups did not differ according to either total ICS dose received or
change in dose over 12 months’ follow-up. Moreover, neither group showed a significant
reduction in ICS. Exacerbation frequency did not differ significantly between the two groups
irrespective of whether exacerbations were or were not associated with an URTI. Similar
results were found in a planned subgroup analysis restricted to atopic participants, although
power may have been limited by the smaller numbers included in this analysis.
Inhaled corticosteroid dose
FENO monitoring theoretically offers a means of matching ICS to eosinophilic inflammation.
Adult studies have shown some reduction in corticosteroid dose with a FENO-based strategy
[2]. Conversely, significantly increased corticosteroid doses have been found in paediatric
studies [15;17]. In this study, although neither the total ICS dose nor change in dose over 12
months’ follow-up differed significantly according to management group, non-significant
differences were seen supporting higher ICS prescription in the FENO group. Lower doses in
the standard management group may have occurred in part as a consequence of the protocol
design; dose reduction in the FENO arm required both low FENO and good symptom control,
whilst good symptom control alone was sufficient for dose reduction under standard
management. In contrast, the adult study which detected a reduction in corticosteroid dose in
the FENO arm followed a protocol whereby the dose increased in the FENO group only if
FENO rose above threshold, whilst under standard management any of five control-based
criteria triggered a dose increase [13].
13
Exacerbation frequency
Whilst conventional markers of asthma control poorly predict exacerbations, there is some
evidence that exacerbations can be predicted using FENO [26]. It has been hypothesised that
FENO-based interventions might tailor inhaled corticosteroid dose in a manner which
reduces exacerbations. Decreased exacerbations might justify small increases in ICS dose.
Whilst paediatric patients assigned to FENO-based management have been shown to be at
reduced risk of requiring one or more oral steroid course [17], only two adult studies have
shown a statistically significant reduction in exacerbation frequency [27, 28]. Previous
paediatric studies have generally recruited relatively mild asthmatics who would be expected
to experience infrequent exacerbations. This study recruited moderate-severe asthmatics in
whom a higher frequency of exacerbations could be expected. Follow-up at 2-monthly
intervals reflected a compromise between providing adequate opportunity for dose
modification and avoiding non-specific reduction of exacerbation frequency across both
groups consequent upon regular follow-up. Exacerbation frequency in this study was greater
than that in many previous studies but, despite this, reduced exacerbation frequency was not
seen in the FENO group. This may reflect greater control in closely monitored participants;
the exacerbation frequency was lower in both groups than that reported for the previous year
and this may have limited the possibility for further improvement by FENO-monitoring.
Strengths and limitations of this study
This study employed a pragmatic design to reflect clinical management of moderate-severe
asthma in paediatric outpatients. Almost 100 children were recruited and participants in this
study had a greater severity of asthma compared to similar trials. Treatment adherence was
emphasised at each visit. Two cut-offs were used to up- and down-titrate ICS according to
FENO level, using a similar protocol, the successful adult trial in pregnant women [27], and
14
provision was made within the protocol to prevent dose escalation at high FENO levels. The
two groups were well matched for clinical and demographic features; although the standard
management group contained more males and its members had more past hospital admissions,
neither of these factors was significantly associated with the main outcomes and therefore
they were unlikely be confounders. By chance, the median FENO level was lower in those
randomised to the FENO group but this difference was not statistically significant. As the
range of participants’ FENO values in each group wide and almost entirely overlapping, this
is unlikely to have biased the study results.
Given the theoretical advantage of tailored ICS the lack of empirical support for FENO-based
interventions is unexpected. It may be argued that, as FENO levels were not significantly
decreased in the FENO group during this study, airway inflammation was not effectively
suppressed. Constant low FENO, however, is not necessarily the aim of FENO-based
monitoring; rather variation in FENO might reflect variation in airway inflammation thereby
improving ICS prescription by providing more sensitive dose titration than that based upon
conventional markers of asthma control. Further explanations are required for the inability to
demonstrate a clinically useful effect of FENO monitoring.
Aspects of protocol design might in part be responsible for lack of success in this and
previous studies [13-15, 16,17]. For example, the long run-in period in this study may have
optimised management thereby limiting further improvement. FENO-driven therapy may
have been more effective if the study had been restricted to atopic-asthma [29]. Choice of
FENO cut-off or the frequency of monitoring and dose adjustment might also affect study
outcomes. There may be a need for ICS dosages to be increased more dramatically in the face
of a high FENO level to adequately suppress airway inflammation. Disappointingly, however,
15
studies using intensive telemonitoring [18] or sophisticated multi-level FENO cut-offs [17] to
address these issues have failed to reveal a benefit associated with FENO monitoring.
It is becoming evident that factors other than protocol design might account for the lack of
success of this and similar studies. Given that sputum eosinophil-based management has been
used successfully to reduce exacerbations [2], it is possible that FENO-based strategies are
unsuccessful because FENO does inaccurately represents eosinophilic inflammation.
Moreover, we now know that FENO provides little useful information regarding noneosinophilic inflammation, for example high levels of neutrophilic inflammation may be
associated with reduced FENO independent of eosinophil number [30]. We have recently
shown that FENO has been shown to correlate more closely with atopy than with asthma and
to vary little with increasing frequency of wheezing attacks in non-atopic asthmatics [29]. It
appears that high FENO levels in some individuals cannot be reduced by higher
corticosteroid doses [31], possibly because of retrograde flow in association with severe
rhinitis. These findings suggest that FENO is influenced by factors other than asthma and that
in some patients, non-invasive markers of airway inflammation are disconnected from asthma
symptoms [32]. Together these factors suggest the efficacy of FENO-guided strategies may
vary according to the population in which they are employed and cast doubt upon the
appropriateness of pre-defined FENO cut-offs.
Empirical support for FENO-based management has been found in atopic and in obese
subjects [17]. This study considered the issue of atopy but was not adequately powered to
support sub-analyses. Theoretically increased effectiveness compared to conventional
management might be expected in subjects discordant for FENO levels and symptoms.
Patients who show an increase in FENO following ICS reduction whilst experiencing no
16
immediate deterioration in symptoms might represent a subgroup in which FENO-based
management is most successful, identifying and randomising such individuals might
represent an optimal trial paradigm.
The FENO cut-off used to direct treatment decisions is critical and may explain differences
seen between studies; too low a cut-off predisposes to higher inhaled corticosteroid doses in
the FENO group whilst too high might fail to reduce exacerbation frequency. FENO
standardised by an individual’s previous best value has been demonstrated to correlate with
asthma control [9]. An alternative to pre-defined cut-offs might be to adjust corticosteroid
dose according to an individual’s personal best FENO level; this has yet to be assessed.
Conclusions
No difference was found in either the inhaled corticosteroid dose or the exacerbation
frequency between children with moderate-severe asthma randomised to either standard or
FENO-based management. Furthermore, no particular benefit was found for atopic children.
At present there is little evidence to support the use of FENO monitoring in routine outpatient
management of paediatric asthma.
ABBREVIATIONS
FENO
Fractional exhaled nitric oxide
FEV1
Forced expiratory volume in 1 second
ICS
Inhaled corticosteroid therapy
IQR
Interquartile range
LABA
Long-acting beta-agonist
PAQLQ
Paediatric asthma quality of life assessment
17
PEF
Peak expiratory flow
COMPETING INTERESTS: None
ACKNOWLEDGEMENTS
Funding for the study was kindly provided by Sparks. The authors would like to acknowledge
the staff at the four sites who helped with the study, in particular the Wellcome Trust Clinical
Research Facility team in Southampton, Selena Lovick, Tricia McGinty, Alyson Dennis,
Jason Witts, Sharon Matthew, Cathy Wilby, Arun Gulati and Peter Whaley. The authors
would also like to thank the participants and their families.
18
REFERENCES
1. Synek M, Beasley R, Frew AJ, et al. Cellular infiltration of the airways in asthma of
varying severity. Am J Respir Crit Care Med 1996: 154: 224-230.
2. Green RH, Brightling CE, McKenna S, et al. Asthma exacerbations and sputum eosinophil
counts: a randomised controlled trial. Lancet 2002: 360: 1718.
3. Vignola AM, Rennar SI, Hargreave FE, et al. Standardised methodology of sputum
induction and processing. Future directions. Eur Respir J 2002: 37: 51s-55s.
4. Wilson NM, James A, Uasuf C, et al. Asthma severity and inflammation markers in
children. Pediatr Allergy Immunol 2001: 12: 125-132.
5. Jatakanon A, Lim S, Barnes PJ. Changes in sputum eosinophils predict loss of asthma
control. Am J Respir Crit Care Med 2000: 161: 64-72.
6. Baraldi E, de Jongste JC. European Respiratory Society, & American Thoracic Society
2002, Measurement of exhaled nitric oxide in children. Eur Respir J. 2001: 20(1): 223-237.
7. Baraldi E, Carrà S, Dario C, et al. Effect of natural grass pollen exposure on exhaled nitric
oxide in asthmatic children. Am J Respir Crit Care Med 1999: 159: 262-266.
8. Brussee JE, Smit HA, Kerkhof M, et al. Exhaled nitric oxide in 4-year-old children:
relationship with asthma and atopy. Eur Respir J 2005: 25: 455-461.
19
9. Roberts G, Hurley C, Bush A, Lack G. Longitudinal study of grass pollen exposure,
symptoms, and exhaled nitric oxide in childhood seasonal allergic asthma. Thorax 2004:
59(9): 752-756.
10. Sippel JM, HoldenWE, Tilles SA, et al. Exhaled nitric oxide levels correlate with
measures of disease control in asthma. J Allergy Clin Immunol 2000: 106: 645-650.
11. Frank TL, Adisesh A, Pickering AC, et al. Relationship between exhaled nitric oxide and
childhood asthma. Am J Respir Crit Care Med 1998: 158: 1032-1036.
12. Baraldi E, Azzolin NM, Zanconato S, Dario C, Zacchello F. Corticosteroids decrease
exhaled nitric oxide in children with acute asthma. J Pediatr 1997: 131: 381-385.
13. Smith AD, Cowan JO, Brassett KP, Herbison GP, Taylor DR. Use of Exhaled Nitric
Oxide Measurements to Guide Treatment in Chronic Asthma. N Engl J Med 2005: 352:
2163-2173.
14. Pijnenburg MW, Bakker EM, Hop WC, De Jongste JC.Titrating steroids on exhaled nitric
oxide in asthmatic children: a randomized controlled trial. Am J Respir Crit Care Med 2005:
172: 831-836.
15. Fritsch M, Uxa S, Horak F Jr, et al. Exhaled nitric oxide in the management of childhood
asthma: a prospective 6-months study. Pediatr pulmonol 2006: 41: 855-862.
20
16. Petsky HL, Cates CJ, Li AM, Kynaston JA, Turner C, Chang AB Tailored interventions
based on exhaled nitric oxide versus clinical symptoms for asthma in children and adults.
Cochrane Database Syst Rev 2009, Issue 4. Art. No.: CD006340. DOI:
10.1002/14651858.CD006340.pub3.
17. Szefler SJ, Mitchell H, Sorkness CA, et al. Management of asthma based on exhaled
nitric oxide in addition to guideline-based treatment for inner-city adolescents and young
adults: a randomised controlled trial. Lancet 2008: 372: 1065-1072.
18. De Jongste JC, Carraro S, Hop WC, Baraldi E; CHARISM Study Group. Daily
telemonitoring of exhaled nitric oxide and symptoms in the treatment of childhood asthma.
Am J Respir Crit Care Med 2009: 179: 93-97.
19. American Thoracic Society. Standards for the diagnosis and care of patients with chronic
obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis 1987: 136:225-244.
20. Juniper EF, Guyatt GH, Feeny DH, Ferrie PJ, Griffith LE, Townsend M. Measuring
quality of life in children with asthma. Qual Life Res 1996: 5: 35-46.
21. Selby A, Clayton B, Grundy J, Pike K, Drew K, Raza A, Kurukulaaratchy R, Arshad SH,
Roberts G. Are exhaled nitric oxide measurements using the portable NIOX MINO®
repeatable across age, gender and lung function? Respiratory Research 2010; 11:43
22. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry, Eur Respir J.
2005: 26(2): 319-338.
21
23. Wasserfallen JB, Gold K, Schulman KA, Baraniuk JN. Development and validation of a
rhinoconjunctivitis and asthma symptom score for use as an outcome measure in clinical
trials. J Allergy Clin Immunol 1997: 100: 16-22.
24. O'Byrne PM, Barnes PJ, Rodriguez-Roisin R, et al. Low Dose Inhaled Budesonide and
Formoterol in Mild Persistent Asthma. The OPTIMA Randomized Trial. Am J Respir Crit
Care Med 2001: 164: 1392-1397.
25. British Thoracic Society/Scottish Intercollegiate Guidelines Network. British guidelines
on the management of asthma. Thorax 2003: 58(Suppl I): i1-94.
26. Zacharasiewicz A, Wilson N, Lex C, et al. Clinical use of noninvasive measurements of
airway inflammation in steroid reduction in children. Am J Respir Crit Care Med 2005: 171:
1077-1082.
27. Powell H, Murphy VE, Taylor DR, Hensley MJ, McCaffery K, Giles W, Clifton VL,
Gibson PG. Management of asthma in pregnancy guided by measurement of fraction of
exhaled nitric oxide: a double-blind, randomised controlled trial. The Lancet 2011; 378: 983
– 990.
28. Malerba M, Ragnoli B, Radaeli A, Tantucci C. Usefulness of Exhaled Nitric Oxide and
Sputum Eosinophils in the Long-term Control of Eosinophilic Asthma. Chest
2008:134(4 )733-739.
22
29. Scott M, Raza A, Karmaus W, et al. Influence of atopy and asthma on exhaled nitric
oxide in an unselected birth cohort study.Thorax. 2010: 65(3): 258-262.
30 Tseliou E; Bessa V; Hillas G, et a. Exhaled Nitric Oxide and Exhaled Breath Condensate
pH in Severe Refractory Asthma. Chest 2010; 138(1):107–113.
31. Pijnenburg MWH, Bakker EM, Lever S, Hop WC, de Jongste JC. High fractional
concentration of nitric oxide in exhaled air despite steroid treatment in asthmatic children.
Clin Exp Allergy 2005: 35: 920-925.
32. Haldar P, Pavord ID, Shaw D, et al.Cluster Analysis and Clinical Asthma Phenotypes Am.
J. Respir. Crit. Care Med 2008: 178(3): 218-224.
23
Figure 1 Flow of participants through the study, comparison of numbers in the FENO
and standard management groups
Incomplete follow up in FENO group: two dropped out after visit 1, two after visit 2, three
after visit 3 (one with a life threatening exacerbation and one due to non-compliance), one
after visit 4 and two after visit 5. In the standard management group, one participant dropped
out after visits 3, 4 and 5.
Figure 2 Inhaled corticosteroid dose at each visit according to randomisation to either
FENO or standard management group
Points represent median inhaled corticosteroid dose in beclomethasone equivalents (mcg) at
each visit for each group while the bars represent the interquartile range.
Figure 3 Kaplan-Meier survival estimates comparing time to first exacerbation in days
for subjects in the Standard and FENO management groups
Curve represents the proportion of participants in each group who have not experienced an
exacerbation at each time point.
Figure 4 FENO measurements at each visit according to randomisation to either FENO
or standard management group.
Points are geometric mean measurements for each group at each visit with bars representing
95% confidence intervals.
24
Table 1. Algorithm for managing asthma
FENO group
FENO level
Poorly controlled asthma
Asthma controlled
Well controlled asthma
Increase inhaled corticosteroids
25ppb or
or add LTRA if already at
BTS/SIGN* step 4
Increase inhaled corticosteroids or add LTRA if
FENO more
than twice
baseline
If after increasing by two
already at BTS/SIGN* step 4
BTS/SIGN* steps FENO
remains high do not increase
therapy further
Increase LABA therapy; if dose
>15 to <25ppb
maximal, increase
corticosteroids or add LTRA if
Continue current treatment
already at BTS/SIGN* step 4
Increase LABA; if dose
15ppb
maximal, increase
If asthma controlled for 3 months, reduce inhaled
corticosteroids or add LTRA if
corticosteroids; if dose 400mcg, reduce LABA
already at BTS/SIGN* step 4
Standard management group
Poorly controlled asthma
Asthma controlled
Well controlled asthma
Increase inhaled corticosteroids or add LABA
No change in inhaled
If well controlled for 3
and/or LTRA as directed by stepwise approach to
corticosteroids
months, reduce inhaled
therapy BTS/SIGN*
corticosteroids; if dose
400mcg, reduce LABA
*United Kingdom guidelines on asthma [25]. Levels of asthma therapy are detailed in Table
2. LABA: long-acting bronchodilator; LTRA: leukotriene receptor antagonist.
25
Table 2 Asthma therapy levels
Step Option 1
Option2
Option3
1
No inhaled corticosteroid
No inhaled corticosteroid
No inhaled corticosteroid
2
Beclometasone 50mcg twice
Budesonide 50mcg twice a
Fluticasone 50mcg once a
a day via spacer
day via spacer (or turbohaler)
day via spacer (or accuhaler)
Beclometasone 100mcg twice
Budesonide 100mcg twice a
Fluticasone 50mcg twice a
a day via spacer
day via spacer (or turbohaler)
day via spacer (or accuhaler)
Beclomethasone 200mcg
Budesonide 200mcg twice a
Fluticasone 100mcg twice a
twice a day via spacer
day via spacer (or turbohaler)
day via spacer (or accuhaler)
Trial of LABA. If ineffective,
Trial of LABA. If ineffective,
Trial of LABA. If ineffective,
consider trial of LTRA.
consider trial of LTRA.
consider trial of LTRA.
Fluticasone 125mcg twice a
Fluticasone 125mcg twice a
Fluticasone 125mcg twice a
day via spacer
day via spacer
day via spacer
Fluticasone 250mcg twice a
Fluticasone 250mcg twice a
Fluticasone 250mcg twice a
day via spacer
day via spacer
day via spacer
Consider short course of
Consider short course of
Consider short course of
prednisolone or other
prednisolone or other
prednisolone or other
therapeutic options.
therapeutic options.
therapeutic options.
3
4
5
6
7
8
Levels of asthma therapy. Modified from British guidelines on the management of asthma
[25]. LABA: long-acting bronchodilator. LTRA: leukotriene receptor antagonist.
26
Table 3 Comparison of the baseline demographic and clinical features of children in the
FENO and standard management groups.
FENO group
Standard
(n=44)
management
p-value
group (n=46)
Demographics
Age years mean (SD)
10.51 (2.62)
11.42 (2.69)
0.107
Male gender (%)
21 (47.7%)
30 (65.2%)
0.094
Gestation weeks median (IQR)
40 (38-41)
40 (38-40)
0.137
Median birth weight in kg (IQR)
3.23 (2.72-3.52)
3.29 (2.81-3.57)
0.924
Caucasian ethnicity (%)
41 (93.2%)
44 (95.7%)
0.609
Recruited from tertiary centre (%)
28 (63.6%)
30 (65.2%)
0.984
Age at diagnosis in years median (IQR)
1 (1 – 2)
2 (1 – 2)
0.514
Median exacerbations in last year (IQR)
3.5 (2 – 8)
4.5 (2 – 7)
0.519
Median oral corticosteroids courses last year
1 (0 – 3.5)
2 (0 – 3)
0.549
2 (0 – 5)
4 (1 – 8)
0.096
Maternal asthma (%)
18 (40.9%)
12 (26.1%)
0.136
Father asthma (%)
15 (34.1%)
13 (28.3%)
0.550
Household smoke exposure (%)
4 (9.1%)
6 (13.0%)
0.551
Atopy (%)
30 (81.1%)
38 (88.4%)
0.363
130.5 (101.0-
125.0 (113.0-142.0) 0.936
History of severity
(IQR)
Median number of hospital admissions ever
(IQR)
Risk factors and exposures
Baseline status and treatment
Median PADQLQ (IQR)
145.0)
Asthma uncontrolled at screening (%)
12 (27.3%)
16 (34.8%)
0.709
27
Mean baseline FEV1 (SD)
87.2 (15.3)
91.1 (13.2)
0.193
Mean FEV1 reversibility (SD)
6.39% (6.24)
6.96% (6.67)
0.677
Median initial beclomethasone equivalent (IQR)
750 (400-1000)
800 (400-1000)
0.629
Prescribed serevent/eformetol (%)
32 (72.7%)
36 (78.3%)
0.541
Prescribed montelukast (%)
22 (50.0%)
24 (52.2%)
0.837
Prescribed theophylline (%)
4 (9.1%)
2 (4.4%)
0.367
Prescribed omalizumab (%)
0 (0%)
0 (0%)
For continuous outcomes, means were compared by t-tests unless the data were skewed when
non-parametric tests were used. Chi-squared tests were used to compare categorical outcomes.
PADQLQ: Paediatric quality of life questionnaire score. IQR: interquartile range.
28
Table 4 Comparison of inhaled steroid therapy and annual exacerbation frequency in the FENO and standard therapy groups.
Median initial
Median final
Median
Median total corticosteroid
Median number of
Perentage of
corticosteroid dose
corticosteroid
corticosteroid
dose (IQR)
exacerbations
subjects with
(IQR)
dose (IQR)
dose change
(IQR)
exacerbations
(IQR)
FENO group
750 (400 to 1000)
800 (400 to 1000)
0 (−200 to 300)
264,800 (164,400 to 350,000)
3 (1-5)
84.1
Standard
800 (400 to 1000)
500 (400 to 1000)
0 (−300 to 0)
249,600 (140,000 to 365,300)
2 (1-4)
82.6
0.629
0.543
0.297
0.555
0.290
0.850
management
P-value
Table includes data from all 90 randomised subjects. All doses are beclomethasone equivalents in micrograms. Median change in corticosteroid
dose is the median of the differences between the doses at the initial and final visits. The total corticosteroid dose is the total dose received
during 12 months follow-up assuming the dose reported at each visit accurately represents that taken for the preceding 2 months and
extrapolating where necessary from the final dose in cases of incomplete follow-up. Exacerbation data was also extrapolated where a participant
did not provide 12 months of data. P-values represent a two sample Mann-Whitney rank-sum test of the between groups difference of exacerbation
frequency and chi-squared test for percentage in each group experiencing exacerbation.
29
30